Get started
Author

Tadakazu Hisamatsu

Observed name: Hisamatsu Tadakazu
Institution: Kyorin University
ORCID: 0000-0002-1178-3536
Observed ORCID: 0000-0002-1178-3536
OpenAlex ID: A5112317852
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113
PDF
Analysis of Clinical Course and Long-Term Prognosis of Surgical and Nonsurgical Patients With Intestinal BehçEt's Disease
2000 · Makoto Naganuma, Yasushi Iwao, et al. · The American Journal of Gastroenterology · 65
Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
2024 · Ken Takeuchi, Tadakazu Hisamatsu, et al. · Digestion · 8
PDF
Lifestyle restrictions are associated with impaired quality of life but not reduction in relapse in ulcerative colitis
2025 · Hajime Yamazaki, Masakazu Nagahori, et al. · Intestinal Research · 5
PDF
800: Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Ulcerative Colitis: Results Through Week 24 From the Phase 3 Astro Study
2025 · Millie D. Long, Jessica R. Allegretti, et al. · Gastroenterology · 2
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data
2025 · Katsuyoshi Matsuoka, Satoshi Motoya, et al. · Journal of Gastroenterology · 2
PDF
S1452 Guselkumab Maintenance Dose Regimens in Patients With High Disease Activity and Severity: Subgroup Analysis of Participants With Moderately to Severely Active Crohn’s Disease in the GALAXI Phase 3 Studies
2025 · Anita Afzali, Tadakazu Hisamatsu, et al. · The American Journal of Gastroenterology · 1
S1984 Efficacy of Retreatment With Upadacitinib After Treatment Interruption in Ulcerative Colitis: Data From the U-ACTIVATE Open-Label Extension
2025 · Remo Panaccione, Jean-Frederic Colombel, et al. · The American Journal of Gastroenterology · 1
A case of ulcerative colitis in a patient undergoing surgery due to exacerbation resulting in toxic megacolon after SARS-CoV-2 vaccination
2025 · Ryota Ogihara, Minoru Matsuura, et al. · Clinical Journal of Gastroenterology · 1
Long-term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Crohn’s Disease: Results From the Vivid-2 Open-label Extension Study
2025 · Edward Barnes, Bruce Sands, et al. · Inflammatory Bowel Diseases · 1
S1586 Efficacy of Guselkumab in Moderately to Severely Active Ulcerative Colitis by Extent of Disease and Inflammatory Burden: Subgroup Analysis of the Phase 3 QUASAR Maintenance Study
2025 · Jessica R. Allegretti, Tadakazu Hisamatsu, et al. · The American Journal of Gastroenterology
S1860 Pharmacokinetics and Exposure-Response Relationships of Guselkumab Intravenous or Subcutaneous Induction in Participants With Ulcerative Colitis
2025 · Laurent Peyrin-Biroulet, Zhenhua Xu, et al. · The American Journal of Gastroenterology
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
2025 · Remo Panaccione, Gil Y. Melmed, et al. · Clinical Gastroenterology and Hepatology
P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants
2025 · Vipul Jairath, Fernando Magro, et al.
Tu1894: EARLY HISTOLOGIC RESPONSE AND REMISSION ARE STRONGLY ASSOCIATED WITH OBJECTIVE CONTROL OF INFLAMMATION AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE
2025 · Fernando Magro, Vipul Jairath, et al. · Gastroenterology
Tu1814: LONG-TERM EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT FOR CROHN’S DISEASE: RESULTS FROM THE VIVID-2 OPEN-LABEL EXTENSION STUDY
2025 · Edward L. Barnes, Bruce E. Sands, et al. · Gastroenterology
Long-term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Crohn’s Disease: Results From the Vivid-2 Open-label Extension Study
2025 · Edward Barnes, Bruce Sands, et al. · Gastroenterology
Usefulness of Monitoring Disease Activity With Intestinal Ultrasound for Ulcerative Colitis
2025 · Jun MIYOSHI, Hiromu Morikubo, et al. · Ultrasound in Medicine & Biology
S73 Subgroup Analysis of Ozanimod Efficacy by Prior Biologic Exposure in Japanese Patients With Ulcerative Colitis from the Phase 2/3 J-True North Study
2024 · Hiroshi Nakase, Tadakazu Hisamatsu, et al. · The American Journal of Gastroenterology
S1351 Improvement in Fatigue With Mirikizumab Therapy and Associations With Clinical Outcomes in Patients With Moderately to Severely Active Crohn’s Disease: Results From the PHASE 3 VIVID-1 Study
2024 · Peter Bossuyt, Miguel D Regueiro, et al. · The American Journal of Gastroenterology
A case of acute obstructive cholangitis seemed to be caused by administration of Amiodarone
2019 · Kazushige Ochiai, Toki Masao, et al.
膵癌早期診断における糖鎖修飾リボヌクレアーゼ1(RNase1)とCA19-9の有用性の検討
2019 · Toki Masao, Daisuke Nakata, et al.
Identification of a novel disease entity, chronic enteropathy associated with SLCO2A1 (CEAS)
2017 · Hisamatsu Tadakazu, Junji Umeno, et al. · 日本消化管学会総会学術集会プログラム・抄録集
これ一冊でわかる 消化器 診断基準と分類法 III 炎症性疾患 6 腸管Behcet病
2017 · Hisamatsu Tadakazu · 診断と治療
Works count: 28
Citation count: 331
H-index: 5
I10-index: 3
Year
Topic
Type